Skip to main content

Table 1 Anti-MCV, anti-CCP, and IgM-RF antibodies in the control patients according to the diagnosis

From: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

Number (percentage) of patients with positive antibodies
  Anti-MCV Anti-CCP IgM-RF
  Cutoff
20 U/mL
Cutoff
28 U/mL
  
Psoriatic arthritis (n = 51) 6 (11.8) 5 (9.8) 5 (9.8) 5 (9.8)
Primary Sjögren syndrome (n = 58) 6 (10.3) 6 (10.3) 6 (10.3) 15 (25.8)
Ankylosing spondylitis (n = 49) 3 (6.1) 2 (4.1) 1 (2) 1 (2)
Healthy controls (n = 50) 5 (10) 0 (0) 0 (0) 0 (0)
Total (n = 208) 20 (9.6) 13 (6.2) 12 (5.8) 21 (10.1)
  1. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor.